China National Pharmaceutical Group, also known as Sinopharm, is mulling a renewed offer for China Traditional Chinese Medicine Holdings that could value the drugmaker at roughly $4B, Bloomberg reports, citing people with knowledge of the matter said. Sinopharm, which holds a controlling stake in China TCM, is discussing a new bid with advisers to potentially take the company private at HK$6 per share. Reference Link
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SHTDF: